Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.64 +0.08 (+0.58%)
Streaming Delayed Price Updated: 11:55 AM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Hutchmed scores U.S. success with cancer drug, but profits still dip ↗
Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla The company plans to focus on innovative drugs... 
Via Benzinga
News headline image
HUTCHMED Reports 2024 Interim Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Why HUTCHMED Stock Is Moving Higher Friday ↗
HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status. 
Via Benzinga
News headline image
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2024 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
News headline image
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.